Deerfield Management Company »

Iteos Therapeutics shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Iteos Therapeutics (ITOS) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Iteos Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Iteos Therapeutics held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Iteos Therapeutics by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $7.9M 723k 10.95
2023-09-30 $7.9M 723k 10.95

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Iteos Therapeutics

RA Capital Management
Boxer Capital
Vanguard Group
BVF
Citadel Advisors
EcoR1 Capital
Millennium Management
Dimensional Fund Advisors
Goldman Sachs Group
Deerfield Management Company
683 Capital Management
Jacobs Levy Equity Management
Artal Group
Ikarian Capital
Citigroup

View all funds holding Iteos Therapeutics